CervoMed Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z
CervoMed Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Mar 17 2026 in planned Phase 3 trial (Phase 3) using Small Molecule.
| Asset | Indication | Modality | Stage | Public Note |
|---|---|---|---|---|
| Introducing Neflamapimod | n/a | Small Molecule | Preclinical | Public pipeline row |
| Mar 17 2026 | planned Phase 3 trial | n/a | Phase 3 | Public pipeline row |
| Mar 12 2026 | n/a | n/a | Phase 3 | Public pipeline row |
| Selected Clinical Trials | n/a | Small Molecule | n/a | Public pipeline row |
| Medicines for the Brain | n/a | n/a | Phase 3 | Public pipeline row |
| Neflamapimod | Dementia With Lewy Bodies | n/a | Phase 2 | Public pipeline row |
Estimated cash runway: Runway < 6 months.
This is an automated estimate and may differ from company guidance.
| NCT ID | Phase | Status | Enrollment | Primary Completion |
|---|---|---|---|---|
| NCT05869669 | Phase 2 | COMPLETED | 159 | 2024-10-04 |
| NCT06815965 | Phase 2 | ACTIVE_NOT_RECRUITING | 25 | 2026-03 |
| NCT06987643 | Phase 2 | RECRUITING | 90 | 2026-05-31 |
| NCT07033481 | Phase 2 | RECRUITING | 20 | 2026-09 |
Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.
Get the weekly biotech catalyst watchlistThis page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.